PPARA and Parkinson disease: The study by Lee et al. [73] demonstrated the neuroprotective effects of the PPAR-α/γ dual agonist MHY908 in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-evoked Parkinson’s experimental model.